Immunalgia Therapeutics is determined to change the future of chronic pain treatment, by using a disruptive technology based on small fractions of synthetic oligonucleotides. These molecules were identified, characterized and patented by our team and belong to a family of molecules commonly called Damage-Associated Molecular Patterns (DAMPs). These molecules mimics natural alert signals for the immune system, which reacts by triggering in the patient himself a strong immuno-modulating and analgesic response that prevents and reverts pain of inflammatory and neuropathic origin. In short, they stimulate the patient’s own cells to solve the problem.